DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer

The majority of patients develop resistance against suppression of HER2-signaling mediated by trastuzumab in HER2 positive breast cancer (BC). HER2 overexpression activates multiple signaling pathways, including the mitogen-activated protein kinase (MAPK) cascade. MAPK phosphatases (MKPs) are essent...

Descripción completa

Detalles Bibliográficos
Autores principales: Menyhart, Otília, Budczies, Jan, Munkácsy, Gyöngyi, Esteva, Francisco J., Szabó, András, Miquel, Teresa Puig, Győrffy, Balázs
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652774/
https://www.ncbi.nlm.nih.gov/pubmed/29100381
http://dx.doi.org/10.18632/oncotarget.20430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652774/
https://www.ncbi.nlm.nih.gov/pubmed/29100381
http://dx.doi.org/10.18632/oncotarget.20430

Ejemplares similares